Cipla Health, a leading player in the wellness category, announced the launch of Astaberry, its beauty and personal care ...

Common flu, seasonal throat infections, and fevers are on the rise in India, making it imperative to practice every day self-care and community protection. Leading the charge, Cipla Health Ltd ...

Cipla USA Inc. (Cipla USA) announced its continued collaboration with the American Lung Association for the 11th annual LUNG FORCE Walk, reaffirming its commitment to advancing respiratory health ...

Cipla reported a 30% YoY increase in net profit, reaching Rs 1,222 crore for Q4, with revenue rising 9% to Rs 6,730 crore. For FY25, revenue grew 8% to Rs 27,548 crore.

Cipla Ltd reported a robust 30% YoY increase in consolidated net profit, reaching Rs 1,222 crore for Q4 FY25, driven by strong sales in India, the US, and Africa.

Cipla receives USFDA approval for generic protein-bound paclitaxel, a cancer treatment drug, expected to launch soon.

Cipla Limited on Tuesday announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% ...

Cipla shares rose 2.78 per cent to hit a high of Rs 1,602.70 on BSE. The pharma stock is up 26 per cent year-to-date.

Cipla , India's third-largest generic drugmaker by sales, reported a 15.2% rise in second-quarter profit that beat estimates, driven by higher sales of its respiratory and cancer drugs in its key ...

Cipla’s success in the US market is a significant growth driver. This success is attributed to new product launches, seasonal factors, and a strong market position in key assets.

The development is a dampener for Cipla, which planned to launch Abraxane, a high-value drug used to treat pancreatic cancer, in Q4.

Cipla’s lanreotide injection is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors.